<DOC>
	<DOCNO>NCT01624805</DOCNO>
	<brief_summary>The goal clinical research study learn horse anti-thymocyte globulin ( hATG ) , give combination methylprednisolone , cyclosporine , G-CSF ( filgrastim pegfilgrastim ) , help control AA and/or low-int-1 risk MDS . The safety drug combination also study . hATG make horse blood target immune cell know T-lymphocytes . Since T-lymphocytes believed involve cause low blood count AA case MDS , kill cell may help treat disease . Methylprednisolone cyclosporine work suppress immune cell call lymphocyte . This may help improve low blood count AA case MDS . Filgrastim pegfilgrastim design cause white blood cell grow . This may help fight infection help improve white blood cell count .</brief_summary>
	<brief_title>Horse ATG Patients With Aplastic Anemia ( AA ) Low/Int-1 Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , admit hospital . On first day , start hATG , small amount dilute hATG injected skin make sure allergic . If reaction , test may do . If reaction severe , take study . On Days 1-4 receive methylprednisolone vein 10 minute . You receive hATG vein 8 hour . If able tolerate ATG without significant side effect , hospital 4-5 day . On Days 1-180 take cyclosporine mouth 2 time day time every day . On Day 5 ( start Day 5 ) receive filgrastim pegfilgrastim injection skin . Your doctor decide drug receive . If receive pegfilgrastim , receive one time Day 5 . If receive filgrastim , receive start Day 5 . You continue receive blood count recover . You give standard drug help decrease risk side effect . You may give drug call eltrombopag help increase platelet count low platelet complication relate low platelet . You may ask study staff information drug give risk . Study Visits : One time weekly first 4-6 week 1 time month Months 2-6 - Your complete medical history record . - You physical exam , include measurement height , weight , vital sign ( blood pressure , heart rate , breathe rate , temperature ) . - Blood ( 2 tablespoon ) draw routine test . At end Month 3 doctor think need , bone marrow aspirate/biopsy check status disease . Length Treatment : You may continue take study drug 6 month . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete follow-up visit . Follow-Up Visits : When treatment , every 6-12 month call member study staff . You ask side effect may . The phone call take 5-10 minute . This investigational study . hATG , cyclosporine , methylprednisolone , filgrastim/pegfilgrastim FDA approve commercially available use patient AA MDS . The use filgrastim/pegfilgrastim drug combination investigational . Up 100 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Patients diagnosis MDS ( Low , Int1 IPSS , hypocellular ) either previously treat untreated eligible trial . 2 . Patients diagnosis aplastic anemia either previously treat untreated eligible currently candidate allogeneic stem cell transplant . 3 . All age eligible . 4 . Patients must cytotoxic , immunosuppressive ( except steroid ) , target therapy least 2 week prior enter study , recover toxic effect therapy grade 1 less . 5 . Adequate organ function define : liver function ( bilirubin &lt; 2mg/dL , AST &lt; 3 x ULN ) , kidney function ( creatinine &lt; 2.5 x ULN ) . 6 . ECOG performance status &lt; /= 2 . 7 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 8 . A negative urine pregnancy test require within 1 week woman childbearing potential prior enrol trial . 9 . Patient must ability understand requirement study sign informed consent . A sign informed consent patient legally authorize representative require prior enrollment protocol . 10 . Patients indication therapy disease transfusion dependence morbidity associate cytopenia ( ) bleeding , severe fatigue , frequent/multiple infection ( eg . neutropenia ) . 1 . Pregnant woman exclude study . Because unknown potential risk adverse event nurse infant secondary treatment mother study agent , breastfeed discontinue mother treat study . 2 . Known HIV infection 3 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 4 . Patient document hypersensitivity component medication .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Aplastic Anemia</keyword>
	<keyword>AA</keyword>
	<keyword>Low/Int-1 Risk Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>hATG</keyword>
	<keyword>Horse Antithymocyte Globulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte Globulin</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Sandimmune</keyword>
	<keyword>CYA</keyword>
	<keyword>Cyclosporin A</keyword>
	<keyword>Methylprednisone</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Depo-Medrol</keyword>
	<keyword>Medrol</keyword>
	<keyword>Solu-Medrol</keyword>
	<keyword>pegfilgrastim</keyword>
	<keyword>Neulasta</keyword>
	<keyword>PEG-G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>C-CSF</keyword>
	<keyword>Neupogen</keyword>
</DOC>